The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
暂无分享,去创建一个
A. Winston | D. Cooper | M. Law | S. Emery | K. Williams | P. Mallon | C. Satchell | K. Macrae | M. Schutz